Search Results
Your search for ,maY matches 17172 pages
Showing 7501 - 7550Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer
Researchers have developed a method based on artificial intelligence (AI) for the histopathologic diagnosis and grading of prostate cancer. The study, published by Ström et al in The Lancet Oncology, showed that the AI system can be trained to detect and grade prostate cancer from needle biopsy...
Higher 21-Gene Recurrence Score May Be Associated With Increased Risk of Locoregional Recurrence in Patients With Breast Cancer
A new study shows that a test physicians commonly use to guide chemotherapy for patients with breast cancer after surgery may also help them decide whether radiation therapy may be of benefit. Results published by Wendy A. Woodward, MD, PhD, and colleagues in JAMA Oncology suggest patients with an...
Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer May Have Different Rates of Mortality
New research indicates that there is a higher risk of early death among patients with oropharyngeal cancer not associated with human papillomavirus (HPV) vs those whose tumors are HPV-positive. The findings are published by Fullerton et al in Cancer. The incidence of oropharyngeal cancer is...
Molecular Characteristics of Leptomeningeal Melanoma Metastases
Patients with advanced melanoma who develop metastases in the leptomeninges usually have a poor prognosis—most patients only survive for 8 to 10 weeks after diagnosis. One reason for this poor prognosis is that very little is known about the molecular development of leptomeningeal melanoma...
Is There an Association Between Powder Use and Risk of Ovarian Cancer?
As reported in JAMA by O’Brien et al, pooled data from four large U.S.-based prospective cohorts suggest the lack of a significant association between the use of powder in the genital area and an increased risk of ovarian cancer. The investigators noted that the analysis may have not been...
Patient Access to High-Quality Oncologic Pathology Improves Care
Accurate and timely diagnoses are critical components for developing treatment plans for patients with cancer and also for informing prognosis and assessment of responses. Pathologists are an essential part of the oncology team because they have specialized knowledge that helps inform diagnostic...
Does Statin Use Increase Overall Survival in Patients With Colorectal Cancer?
About 40 million adults in the United States take a statin to lower their cholesterol and reduce the risk for heart disease—but they may also be getting an added anticancer benefit, a growing body of evidence suggests. According to research presented at the American Heart Association’s Scientific...
FDA Approves Avapritinib for the Treatment of PDGFRA-Mutated Gastrointestinal Stromal Tumor
On January 9, the U.S. Food and Drug Administration (FDA) approved avapritinib (Ayvakit) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbors platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. This approval includes...
Expert Point of View: Gary Schiller, MD
At the press conference where these data were presented, moderator Gary Schiller, MD, of the University of California, Los Angeles, explained that although chimeric antigen receptor (CAR) T-cell therapy is a major advance in cellular immunotherapy, enabling killing of cancer cells in blood and bone ...
Preliminary Data on Multiantigen-Targeted CAR NK-Cell Therapy for B-Cell Malignancies
A novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product called FT596 may prove to be an active therapy for B-cell malignancies. This agent is designed to overcome several challenges inherent in CAR T-cell therapy, including CD19-antigen escape, which leads to relapse in ...
Step Counts May Help Predict Treatment Outcomes for Patients With NSCLC
A new study suggests step counters could play a role in predicting outcomes for people undergoing chemoradiation therapy for lung cancer. These findings were published by Ohri et al in the International Journal of Radiation Oncology • Biology • Physics. “I consider step counts to be a new vital...
Prevalence of Alcohol Use Among Patients With Cancer and Survivors
New research published by Nina N. Sanford, MD, and colleagues in JNCCN—Journal of the National Comprehensive Cancer Network has found most cancer survivors reported that they are current alcohol drinkers, with a subset of those survivors self-reporting excessive drinking behaviors. “We recommend...
Dietary Supplement Use During Adjuvant Chemotherapy and Treatment Outcomes in Patients With Early Breast Cancer
As reported in the Journal of Clinical Oncology by Ambrosone et al, an analysis of the SWOG S0221 trial population suggests that use of antioxidant and nonantioxidant dietary supplements, but not multivitamins, before and during adjuvant chemotherapy may be associated with poorer treatment outcomes ...
Noninferiority of Four vs Six Cycles of CHOP for Patients With Favorable Prognosis B-Cell Lymphoma: FLYER Trial
As reported in The Lancet by Viola Poeschel, MD, and colleagues, the phase III FLYER trial has shown noninferiority of progression-free survival with four vs six cycles of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) in combination with six doses of rituximab in patients with...
Many Pelvic Examinations and Papanicolaou Tests Performed on Young Women May Be Unnecessary
Pelvic examinations and cervical cancer screenings are no longer recommended for most females under age 21 during routine health visits, but a new study has found that millions of young women are undergoing the tests, which can lead to false-positive testing, overtreatment, anxiety, and needless...
Largest Single-Year Drop in Cancer Mortality Reported in ‘Cancer Statistics, 2020’
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017—the largest single-year drop in cancer mortality ever reported. These findings were reported in “Cancer Statistics, 2020,” the latest edition of the American Cancer Society’s annual report on cancer...
Physical Activity at Recommended Levels May Lower Risk of Multiple Cancers
A pooled analysis of nine prospective studies involving more than 750,000 adults has found that recommended amounts of leisure-time physical activity were linked to a lower risk for seven cancers, with several cancer types having a dose/response relationship. These findings were published by...
One Cycle of Bleomycin/Etoposide/Cisplatin May Be as Effective as Two for Patients With Testicular Cancer
Testicular cancer recurrence may be prevented by giving men one cycle of chemotherapy instead of the two cycles used as standard. Lowering the overall exposure to chemotherapy also reduced side effects. These findings were published by Cullen et al in European Urology. Testicular cancer is the most ...
Overall Survival With the Addition of Daratumumab to VMP in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
As reported in The Lancet by Maria-Victoria Mateos, MD, and colleagues, interim analysis of overall survival in the phase III ALCYONE trial has shown a significant benefit of the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in patients with newly diagnosed multiple...
Saliva Test May Play A Role in the Early Detection of HPV-Related Oropharyngeal Cancer
A report by Wang et al in The Journal of Molecular Diagnostics described the use of acoustofluidics, a noninvasive method that analyzes saliva for the presence of human papillomavirus type 16 (HPV-16), the pathogenic strain of the disease associated with oropharyngeal cancers. This novel technique...
FDA Finalizes Enforcement Policy on Unauthorized Flavored Cartridge-Based E-Cigarettes
Amid the epidemic levels of youth use of e-cigarettes and the popularity of certain products among children, the U.S. Food and Drug Administration (FDA) has issued a policy prioritizing enforcement against certain unauthorized flavored e-cigarette products that appeal to children, including fruit...
Asciminib for Patients With CML After Failure of ABL Kinase Inhibitor Treatment
In a phase I trial reported in The New England Journal of Medicine, Hughes et al found that asciminib, an oral BCR-ABL1 inhibitor with a mechanism of action different from available ABL1 tyrosine kinase inhibitors, was active in patients with chronic myeloid leukemia (CML) after failure of ABL...
Screening Rates Rose Among People Aged 45–49 After Release of Updated Colorectal Cancer Guidelines
Colorectal cancer screening rates more than doubled among people aged 45 to 49 in the months after the release of updated American Cancer Society guidelines in 2018 recommending screening in that age group, according to a new study. According to the findings from Fedewa et al—published in...
Preliminary Study Finds ASCO Decision Aid May Improve Quality of Serious Adverse Events Reporting
Sponsors of clinical trials conducted under investigational new drug (IND) applications are required by the U.S. Food and Drug Administration (FDA) to report serious adverse events that are unexpected and suspected to be related to the drug. However, contrary to FDA guidance, investigators often...
CMS Finalizes Updates to E&M Codes, Establishes MIPS Value Pathways
The Centers for Medicare & Medicaid Services (CMS) released its final rule for the 2020 Medicare Physician Fee Schedule (MPFS) and other changes to Medicare Part B reimbursement policies, including proposals related to the Quality Payment Program (QPP). The estimated impact of the final MPFS...
ASCO and IASLC Collaborate to Improve the Quality of Lung Cancer Care in Brazil
Medical oncologists in Brazil are being encouraged to take advantage of a new measure set for assessing the quality of care they provide to patients with lung cancer. Lung cancer is one of the most prevalent and deadly types of cancer in Brazil.1 Providing a platform for health-care providers to...
Trastuzumab and Hyaluronidase-oysk for Subcutaneous Use in HER2-Positive Breast Cancer
Early in 2019, trastuzumab and the endoglycosidase hyaluronidase-oysk for subcutaneous injection was approved in the treatment of HER2-positive breast cancer.1,2 The agent is indicated for adjuvant treatment of patients with HER2-overexpressing node-positive or node-negative (estrogen...
Rituximab-abbs: Biosimilar to Rituximab for Non-Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Late in 2018, rituximab-abbs was approved as the first...
Taking a Reasonable Approach to Treating Newly Diagnosed Multiple Myeloma
Multiple myeloma is a malignancy characterized by clonal proliferation of terminally differentiated plasma cells within the bone marrow. Although it leads to a host of different issues within the body, overall survival has steadily improved in recent years. “This is largely because of better...
KEYNOTE-013 and KEYNOTE-170: Improving the Precision of Checkpoint Blockade in Patients With Diffuse Large B-Cell Lymphoma
Primary mediastinal B-cell lymphoma is an uncommon but distinct clinicopathologic variant of diffuse large B-cell lymphoma (DLBCL) that typically presents with an aggressive mediastinal mass and invasion of local structures. Most patients are young, typically in their 20s and 30s, and there is a...
Time to Treatment Is a Priority
Dr. Smith called us on a Tuesday afternoon. “I have a patient who has an abnormal mammogram showing a large mass. I’m suspecting cancer and am referring her to you for diagnosis and treatment. She’s very anxious. I hope you can help.” We were able to get Dr. Smith’s patient in the next day for...
Expert Point of View: Steven J. Isakoff, MD, PhD
Steven J. Isakoff, MD, PhD, a medical oncologist at Massachusetts General Hospital, Boston, commented on the results of the DESTINY-Breast01 trial. “These data are extraordinarily encouraging, suggesting we will have another new option for patients with metastatic HER2-positive breast cancer. The...
Swedish Study of Risk-Adapted Screening Starting Ages for Relatives of Patients With Breast Cancer
In a study reported in JAMA Oncology, Trasias Mukama, MPH, and colleagues identified risk-adapted screening starting ages for relatives of patients with breast cancer according to the number of affected first-degree and second-degree relatives and the age at diagnosis of affected relatives. The...
Sequencing of Enzalutamide and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
In a Canadian phase II crossover trial reported in The Lancet Oncology, Kim N. Chi, MD, and colleagues found that time to second prostate-specific antigen (PSA) progression from start of treatment was longer with crossover from abiraterone acetate/prednisone to enzalutamide vs the reverse sequence ...
FDA Pipeline: Priority Reviews in SCLC, Bladder Cancer, Colorectal Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for treatments in extensive-stage small cell lung cancer (SCLC), non–muscle invasive bladder cancer, and BRAF V600E–mutant colorectal cancer. The Agency also recently issued multiple Breakthrough Therapy designations and ...
Explaining Risk Factors Related to Anal Cancer
A recent study found rising rates of squamous cell carcinoma of the anus, “particularly advanced-stage disease, and a similar rise in mortality.”1 The authors concluded: “Improved prevention strategies are urgently needed to mitigate the rising [squamous cell carcinoma of the anus] burden among a...
Incidence of Squamous Cell Carcinoma of the Anus Has ‘Increased Dramatically’ in Older Women and Young Black Men
“Squamous cell carcinoma of the anus incidence has increased dramatically in elderly women and young black men,” according to a study of recent trends in incidence and mortality. “Advanced-stage [anal squamous cell carcinoma] incidence tripled with a prominent rise in … mortality,” researchers...
Fractionated Tisagenlecleucel Infusion for Adults With B-Cell Acute Lymphoblastic Leukemia May Improve Safety Without Reducing Efficacy
As reported by Noelle V. Frey, MD, and colleagues in the Journal of Clinical Oncology, single-center experience with the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel has shown that high-dose fractionated infusion with the ability to modify dosing in case of early signs...
The Antiseptic Era: 1876–1900
The text and photographs here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era: 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photographs appear courtesy of Dr. Burns and The Burns Archive. To ...
Dana-Farber Researcher Receives Victoria Mock New Investigator Award From ONS
Robert Knoerl, PhD, RN, an Instructor in Medicine and Nurse Scientist in the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute, has been awarded the 2020 Oncology Nursing Society’s Victoria Mock New Investigator Award. Dr. Knoerl was...
Global Survey Shows Misperceptions About Lung Cancer Among the General Public
Only one in five people (22%) disagrees with the statement “generally, patients with lung cancer have caused their illness through their lifestyle choices and behaviors,” according to a global, omnibus survey conducted by Ipsos MORI and sponsored by the Lung Ambition Alliance. The results were...
Companion Diagnostic Approved for Alpelisib/Fulvestrant Therapy
On December 4, the U.S. Food and Drug Administration (FDA) approved FoundationOne CDx to be used as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of postmenopausal women as well as male patients with hormone receptor–positive, HER2-negative, PIK3CA-mutated,...
American Cancer Society and Flatiron Health Launch Real-World Data Impact Award
The American Cancer Society (ACS) and Flatiron Health has announced the launch of the American Cancer Society & Flatiron Health Real-World Data Impact Award. This joint grant-making program supports both organizations’ goals of accelerating cancer research and improving treatment and care...
Gilteritinib for Relapsed or Refractory AML With FLT3 Mutation
Late in 2018, the FLT3 inhibitor gilteritinib was approved for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA also approved an expanded indication...
Selected Abstracts From the 2019 ASH Annual Meeting & Exposition
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for acute myeloid leukemia (AML). For full details of these...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid ...
Pembrolizumab in Adjuvant Treatment of Melanoma With Involvement of Lymph Nodes After Complete Resection
In early 2019, pembrolizumab was approved for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.1,2 Supporting Efficacy Data Approval was based on findings in the double-blind EORTC 1325/KEYNOTE-054 trial (ClinicalTrials.gov identifier...
Grief Symptom Levels in Parents of Children Who Have Died of Cancer
In a Swedish study reported in the Journal of Clinical Oncology, Pohlkamp et al identified factors associated with levels of prolonged grief symptoms in parents of children who have died of cancer, with factors being found to differ between mothers and fathers.1 As stated by the investigators,...
Acupuncture May Reduce Radiation-Induced Dry Mouth for Patients With Head and Neck Cancer
After receiving acupuncture treatment 3 days a week during the course of radiation treatment, patients with head and neck cancer experienced less dry mouth, according to study results published by Garcia et al in JAMA Network Open. The results are from the first randomized, placebo-controlled,...
Acalabrutinib for Adult Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
On November 21, 2019, the Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib was approved for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The review resulting in approval was conducted under Project Orbis, an initiative of the U.S....
